RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq:SGMO - News) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP Therapeutic® program to develop SB-509 as a treatment for diabetic neuropathy.  A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.

 

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The passcode for the call is 15507481.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 11:30 am ET on October 3, 2011 to midnight ET on October 10, 2011. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406 respectively. The conference ID number for the replay is 15507481.